所有图片(2)
About This Item
经验公式（希尔记法）:
C25H38O5
CAS号:
分子量:
418.57
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
analytical standard
质量水平
方案
≥98.0% (HPLC)
旋光性
[α]/D +275±25°, c = 1 in acetonitrile
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
杂质
≤0.5% water
mp
127-132 °C (lit.)
应用
forensics and toxicology
pharmaceutical (small molecule)
veterinary
包装形式
neat
储存温度
2-8°C
SMILES字符串
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC
InChI
1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
InChI key
RYMZZMVNJRMUDD-HGQWONQESA-N
基因信息
human ... HMGCR(3156)
正在寻找类似产品? 访问 产品对比指南
应用
有关合适仪器技术的更多信息，请参考产品分析证书。如需进一步支持，请联系技术服务。
生化/生理作用
辛伐他汀是HMG-CoA还原酶和降胆固醇药物的特异性抑制剂。
辛伐他汀是HMG-CoA还原酶的特异性抑制剂，HMG-CoA还原酶是催化HMG-CoA转化为甲羟戊酸的酶，其是胆固醇生物合成的早期步骤。由于它可以降低低密度脂蛋白和甘油三酯的水平，并提高高密度脂蛋白水平，因而可用于治疗高胆固醇血症。辛伐他汀是一种内酯，其在体内 易于水解成相应的β-羟基酸，并可以在使用前用溶于EtOH中的NaOH进行活化。它是洛伐他汀的合成类似物（货M2147）。
警示用语：
Warning
危险声明
危险分类
Repr. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Daniel F McAuley et al.
The New England journal of medicine, 371(18), 1695-1703 (2014-10-01)
Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical
L B Ramsey et al.
Clinical pharmacology and therapeutics, 96(4), 423-428 (2014-06-12)
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association
Gerard J Criner et al.
The New England journal of medicine, 370(23), 2201-2210 (2014-05-20)
Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized
Jennifer G Robinson et al.
JAMA, 311(18), 1870-1882 (2014-05-16)
In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3
Stephen J Nicholls et al.
The American journal of cardiology, 105(1), 69-76 (2010-01-28)
Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门